Enliven Therapeutics, Inc. - Common Stock

ELVN46

$23.07arrow_drop_up6.02%$1.31

ELVN46

$23.07

arrow_drop_up6.02%$1.31

Performance History

Key Stats
Open	$22.56
Prev. Close	$21.76
EPS	-1.91
Dividend	Non-Dividend
Next Earnings Date	-
Dividend Yield %	-

PE Ratio	-

	LOW	HIGH
Day Range	21.87	23.60
52 Week Range	9.80	27.67

Ratios

Revenue	-



EBITDA Margin %	-

EPS	-1.91

Score Breakdown

Welcome to Stocklytics

Don't miss out on the opportunity to stay ahead in the ever-changing world of finance.

Analyst Forecast

Period: Next 12 Months

•

Analyst Ratings

•

About Enliven Therapeutics, Inc. - Common Stock (ELVN)

Enliven Therapeutics, Inc. is a pharmaceutical company that specializes in the development of novel therapies for various medical conditions. The company's primary focus is on the research and development of innovative treatments for neurological disorders. With a mission to improve the lives of patients suffering from these debilitating conditions, Enliven Therapeutics is dedicated to finding effective and safe treatments that can make a meaningful difference in patients' lives.

Enliven Therapeutics' flagship product, the ELVN Common Stock, is a promising treatment that has garnered significant attention in the pharmaceutical industry. This stock has shown great potential in the treatment of multiple neurological disorders, including Alzheimer's disease, Parkinson's disease, and epilepsy. The ELVN Common Stock has demonstrated promising results in preclinical and early clinical trials, showing its potential to address the unmet medical needs of patients suffering from these conditions.

Websitecall_made

Sector: Healthcare
Industry: Biotechnology
CEO: Mr. Samuel S. Kintz M.B.A.
Headquarters: Boulder
Employees: 37
Exchange: NASDAQ

add Enliven Therapeutics, Inc. - Common Stock to watchlist

Keep an eye on Enliven Therapeutics, Inc. - Common Stock

Adding the right stocks to your watchlist can provide valuable insights and opportunities for strategic decision-making.

Frequently Asked Questions

help

What is Enliven Therapeutics, Inc. - Common Stock's (ELVN) price per share?

The current price per share for Enliven Therapeutics, Inc. - Common Stock (ELVN) is $23.07. The stock has seen a price change of $1.31 recently, indicating a 6.02% change. This reflects the stock's recent market performance and investor sentiment.

help

What is the 52-week high and low for Enliven Therapeutics, Inc. - Common Stock (ELVN)?

For Enliven Therapeutics, Inc. - Common Stock (ELVN), the 52-week high is $27.67, which is 19.95% from the current price. The 52-week low is $9.8, the current price is 135.41% above the 52-week low. This gives investors an insight into the stock's volatility and price range over the past year.

help

Is Enliven Therapeutics, Inc. - Common Stock (ELVN) a growth stock?

Enliven Therapeutics, Inc. - Common Stock (ELVN) has shown an average price growth of 0.41% over the past three years. It has received a score of 98 out of 100 based on the Stocklytics formula. The interpretation of this score in terms of classifying Enliven Therapeutics, Inc. - Common Stock as a growth stock may vary, considering it is one of many factors investors might evaluate, including market trends, financial performance, and future prospects of the company.

help

What is Enliven Therapeutics, Inc. - Common Stock (ELVN) stock price performance year to date (YTD)?

As of the latest data, Enliven Therapeutics, Inc. - Common Stock (ELVN) has a year-to-date price change of 54.83%. Over the past month, the stock has experienced a price change of -1.95%. Over the last three months, the change has been 9.65%. Over the past six months, the figure is 31.53%.

help

Is Enliven Therapeutics, Inc. - Common Stock (ELVN) a profitable company?

Enliven Therapeutics, Inc. - Common Stock (ELVN) has a net income of -$71.58M, which represents the company's total earnings after all expenses have been deducted from revenues. The gross margin of indicates the percentage of revenue that exceeds the cost of goods sold, and the operating margin of 0% reflects the percentage of revenue remaining after covering variable production costs, highlighting the efficiency of the company's core operations. Total revenue stands at , although specific revenue growth data is currently not available. Operating income is noted at -$83.53M. Furthermore, the EBITDA is -$95.95M.

help

What is the market capitalization of Enliven Therapeutics, Inc. - Common Stock (ELVN)?

Enliven Therapeutics, Inc. - Common Stock (ELVN) has a market capitalization of $1.03B. The average daily trading volume is 141.73K, indicating the stock's liquidity and investor engagement.